Format

Send to

Choose Destination
Drug Des Devel Ther. 2018 Apr 30;12:1009-1017. doi: 10.2147/DDDT.S161199. eCollection 2018.

Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia).

Author information

1
Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China.

Abstract

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy, characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. The new drugs used for treating AML are facing a big challenge, and the candidates include cytotoxic drugs, targeted small-molecule inhibitors, and monoclonal antibodies. In recent years, active research has focused on several new agents for including them in the large antileukemic drug family. This review aims to introduce some of these new drugs and highlights new advances made in the old drugs, mainly in the last 5 years.

KEYWORDS:

2017 NCCN guideline; acute myeloid leukemia; new drug therapies; refractory/relapsed AML

PMID:
29750014
PMCID:
PMC5933364
DOI:
10.2147/DDDT.S161199
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center